Diamond Biotechnology Co (ROCO:6815) Retained Earnings: NT$32.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6815 Diamond Biotechnology Co Ltd ROCO:6815
83 GF Score
Price NT$24.25
GF Value NT$41.70
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Diamond Biotechnology Co Retained Earnings?

Diamond Biotechnology Co ROCO:6815 -3.00% 83 Retained Earnings is NT$32.1 Mil as of Jun. 2026. GuruFocus rates ROCO:6815 with a GF Score™ of 83/100 and a GF Value™ of NT$41.70 (Possible Value Trap). The stock has 7 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Diamond Biotechnology Co's retained earnings for the quarter that ended in Jun. 2026 was NT$32.1 Mil.

Diamond Biotechnology Co's quarterly retained earnings declined from Jun. 2025 (NT$12.5 Mil) to Dec. 2025 (NT$-67.2 Mil) but then increased from Dec. 2025 (NT$-67.2 Mil) to Jun. 2026 (NT$32.1 Mil).

Diamond Biotechnology Co's annual retained earnings increased from Dec. 2023 (NT$49.9 Mil) to Dec. 2024 (NT$76.4 Mil) but then declined from Dec. 2024 (NT$76.4 Mil) to Dec. 2025 (NT$-67.2 Mil).


Diamond Biotechnology Co  (ROCO:6815) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Diamond Biotechnology Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Diamond Biotechnology Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamond Biotechnology Co Retained Earnings Chart

Diamond Biotechnology Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only 45.08 36.55 49.90 76.36 -67.15

Diamond Biotechnology Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.16 76.36 12.51 -67.15 32.11
ROCO:6815
83GF Score
Diamond Biotechnology Co Ltd ROCO:6815
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamond Biotechnology Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of NT$32.1 Mil mean?
Diamond Biotechnology Co (ROCO:6815) has a Retained Earnings of NT$32.1 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Diamond Biotechnology Co and its competitors.
Is Diamond Biotechnology Co's Retained Earnings too high?
Diamond Biotechnology Co's current Retained Earnings is NT$32.1 Mil. Overall, Diamond Biotechnology Co has a GF Score™ of 83/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Diamond Biotechnology Co's Retained Earnings compare to ABT and SYK?
Diamond Biotechnology Co's Retained Earnings of NT$32.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Diamond Biotechnology Co and its competitors. Diamond Biotechnology Co's current Retained Earnings is NT$32.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Diamond Biotechnology Co (ROCO:6815) is currently considered Possible Value Trap. The stock's GF Value™ is NT$41.70, compared to a current price of NT$24.25 — trading 41.8% below its estimated fair value. The current Retained Earnings is NT$32.1 Mil. Diamond Biotechnology Co's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Diamond Biotechnology Co (ROCO:6815), the current Retained Earnings is NT$32.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamond Biotechnology Co (ROCO:6815) Overvalued in 2026?

Based on GuruFocus' analysis, Diamond Biotechnology Co stock appears to be undervalued. The current stock price of NT$24.25 is trading 41.8% below its estimated GF Value™ of NT$41.70. GuruFocus considers Diamond Biotechnology Co to be Possible Value Trap.

Key valuation signals for ROCO:6815:

  • Retained Earnings: NT$32.1 Mil
  • GF Value™: NT$41.70 vs. price of NT$24.25 (41.8% below fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6815 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diamond Biotechnology Co Business Description

Address No. 45, Section 2, Fuxing South Road, Da'an District, 11th Floor, Taipei, TWN
Diamond Biotechnology Co Ltd is engaged in the research and development of medical equipment, and medical consumables. It also manufactures and sells medical beauty-level skincare products.
83GF Score

Get the complete analysis for ROCO:6815

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.25
Price
NT$41.70
GF Value